Knowledge Library

Fibrosis Models in Mice and Rats

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases.  To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data.  Our platform also includes a …Read More >

Resource Type: Presentation
Resource Topic: Autoimmune and Inflammatory Diseases Liver Diseases NASH Respiratory Diseases

VIEW

Case Study: Clinically Relevant NASH Animal Model

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Resource Type: Case Study Latest Science
Resource Topic: in vivo Pharmacology Liver Diseases Metabolic Diseases NASH

VIEW

Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss. Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo. https://pubmed.ncbi.nlm.nih.gov/36089112/

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Cell-based Assays Discovery Chemistry Hit-to-Lead Infectious Diseases Lead Optimization Liver Diseases Small Molecules

VIEW

Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B

WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006 for treating chronic hepatitis B infection. DF-006 is an orally active agonist of alpha‐kinase 1, a pattern recognition receptor involved in the stimulation of innate immunity.  The authors show that DF‐006 is efficacious in hepatitis …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Infectious Diseases Liver Diseases Small Molecules

VIEW

Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step

WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of a potent and selective inhibitor of Notum carboxylesterase (an enzyme that suppresses Wnt signaling pathways).  By employing a modified Sakai reaction as the key step, a one-pot synthesis of this Notum inhibitor was developed, enabling …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cardiovascular & Metabolic Diseases Discovery Chemistry Liver Diseases Oncology Respiratory Diseases Small Molecules

VIEW

WuXi AppTec Oligonucleotide Biology Platform

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Candidate Selection Cell-based Assays Discovery Chemistry Gene Therapies Hit-to-Lead in vivo Pharmacology Lead Optimization Liver Diseases Oligonucleotides Rare Diseases Safety and Early Toxicity Target-Specific Assays

VIEW

How Does It Work? | RNAi

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. Protein malfunctions cause many diseases, but a new approach is emerging …Read More >

Resource Type: Video
Resource Topic: Autoimmune and Inflammatory Diseases Cardiovascular & Metabolic Diseases Central Nervous System & Pain DRUG DISCOVERY AND INNOVATION Gene Therapies Liver Diseases Metabolic Diseases Oligonucleotides Oncology Ophthalmology Rare Diseases Target Identification and Validation

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies Antibody Drug Conjugate Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Biophysical Assays Candidate Selection CAR-T Cell Cardiovascular & Metabolic Diseases Cell Therapies Cell-based Assays Cells and Protein Science Central Nervous System & Pain Chemical Biology and Proteomics Dermatology Discovery Chemistry DNA-Encoded Library (DEL) DRUG DISCOVERY AND INNOVATION Fragment-Based Drug Discovery Gene Therapies High-throughput screening (HTS) Hit Finding Hit-to-Lead Immunology in silico services in vitro biology in vivo Pharmacology in vivo Toxicology Infectious Diseases Lead Optimization Liver Diseases Mass Spectrometry-based Assays Metabolic Diseases NASH Oligonucleotides Oncology Oncolytic Viruses Ophthalmology Phenotypic Assays Quantum Mechanics Rare Diseases Respiratory Diseases Safety and Early Toxicity Screening Libraries Screening Services Small Molecules Structural Biology Target Identification and Validation Target-Specific Assays Targeted Protein Degradation TECHNOLOGY PLATFORMS THERAPEUTIC AREAS THERAPEUTIC MODALITIES Tumor Models

VIEW

NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis

Resource Type: Webinar
Resource Topic: Biomarkers Lead Optimization Liver Diseases Metabolic Diseases NASH

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!